News & Events

Press Releases

Mar 12

Solid Biosciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

– Biopsy results from the third patient dosed at 2E14 vg/kg in the SGT-001 IGNITE DMD clinical trial provide further support for continued development – – Solid continues to make progress to address the IGNITE DMD clinical hold and advance the next steps for the SGT-001 program – CAMBRIDGE, Mass.

Read More
Jan 09

Solid Biosciences Announces Organizational Changes to Prioritize Development of SGT-001

CAMBRIDGE, Mass. , Jan. 09, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) today announced changes to its organizational structure to create a leaner company focused on advancing SGT-001, a gene transfer candidate for the treatment of Duchenne muscular dystrophy (Duchenne).

Read More